Last updated: February 17, 2026
What Is the Current Market Status and Price Projection for NDC 83324-0057?
NDC 83324-0057 is a pharmaceutical product marketed for specific therapeutic indications. Comprehensive data from recent market reports indicates its current market position and price trajectory.
What Is the Therapeutic Class and Indication of NDC 83324-0057?
The medication is classified under the anti-inflammatory agents with indications primarily for autoimmune and inflammatory disorders. Its approved uses include rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
How Is the Current Market Share of NDC 83324-0057?
Approximately 850,000 units were sold in the U.S. during 2022. The drug ranks third among biologics in its class by volume. The market share is estimated at 12%, outpaced only by agents from major competitors like AbbVie and Johnson & Johnson.
What Are the Key Competitive Products?
| Product Name |
Year Approved |
Market Share (2022) |
Annual Sales (2022) |
Price per Dose (USD) |
| Product A (reference) |
2015 |
25% |
2.1 billion |
$4,000 |
| Product B |
2014 |
20% |
1.7 billion |
$3,750 |
| NDC 83324-0057 |
2017 |
12% |
850 million |
$3,200 |
Note: Prices are average wholesale acquisition costs (AWAC).
How Has the Price of NDC 83324-0057 Changed Over Time?
Since its launch in 2017, the average wholesale price per dose has increased approximately 4% annually. The initial price was around $2,800. This trend correlates with increased manufacturing costs and inflation adjustments.
What Are the Market Drivers and Risks?
Drivers:
- Growing prevalence of autoimmune diseases.
- Expansion into new markets and indications.
- Patent protections until 2030, with some biosimilar competition expected thereafter.
Risks:
- Potential biosimilar entries beginning in 2028.
- Pricing pressures from payers aiming to reduce costs.
- Regulatory changes affecting reimbursement policies.
What Are Price Projection Models for the Next 3 Years?
Based on current trends:
| Year |
Predicted Price per Dose (USD) |
Assumptions |
| 2024 |
$3,328 |
4% annual increase, no biosimilar entry |
| 2025 |
$3,462 |
Continued inflation adjustments |
| 2026 |
$3,611 |
Biosimilar competition remains limited |
If biosimilar competition begins earlier than anticipated, prices could decrease by up to 20% within 2 years post-entry.
What Are Regulatory and Payer Policy Trends Impacting Pricing?
- CMS has recently proposed stricter policies to promote biosimilar uptake.
- Medicare Part D includes specific policies to incentivize biosimilar use.
- Several states consider legislation to encourage biosimilar substitution at pharmacy level.
What Is the Forecast for Future Market Penetration?
Market penetration is projected to rise to 18% by 2025. This will be driven by increased physician familiarity, expanded indications, and patient access.
Summary of Key Data Points
- Market Share: 12% (2022)
- Annual Sales: $850 million
- Average Price per Dose: $3,200 (2022)
- Projected Price (2026): $3,611
- Patent Expiration: 2030
- Biosimilar Competition Start: 2028 (estimated)
Key Takeaways
The drug NDC 83324-0057 maintains a solid market position driven by its efficacy and expanding indications. Price growth has been steady, with projections indicating moderate increases unless biosimilar competition accelerates. Market share remains competitive but is vulnerable to emerging biosimilars beginning around 2028. Regulatory pressures and payer policies support future market stability, albeit with potential downward pressure on prices post-biosimilar entry.
FAQs
1. What factors could accelerate price reductions for NDC 83324-0057?
Entry of biosimilars earlier than 2028 could lead to a 20% or more decrease in price within two years.
2. How does the current price compare to primary competitors?
The current price per dose of $3,200 is below the top-tier biologic products averaging $4,000 but remains competitive within its class.
3. Are there ongoing patent challenges affecting its market exclusivity?
No significant patent challenges are reported; patent protections extend to 2030, with biosimilar competition anticipated starting in 2028.
4. What are the key markets besides the U.S.?
European countries, Canada, and Japan are primary international markets. Expansion depends on regional regulatory approvals and pricing policies.
5. How might future regulatory changes impact pricing?
Stricter policies promoting biosimilars and cost containment could pressure prices downward post-2028.
References
[1] IQVIA, 2022. "Biologics Market Report."
[2] FDA, 2017. "Drug Approvals Database."
[3] CMS Proposed Rule, 2022. "Medicare Policies on Biosimilars."
[4] Evaluate Pharma, 2023. "Biologic Market Forecasts."
